Formulation Freedom in Clinical Development: Why Fill2Weight Matters
In early-stage pharmaceutical development, poor powder flow is rarely the root issue, it’s simply a symptom. The real challenge for formulation...
Dr. Dave Seaward : 20 January 2022
PDF File: Cell and Gene Therapy: Converting a Rolls-Royce into a Ford?
With promising applications in the personalised medicines field, Cell and Gene Therapies are becoming more and more relevant. This, alongside 3Ps experience in the manufacturing of said therapies, has inspired 3P Founder and Projects Director Dave Seaward, to write a new blog series all about ATMPs!
Click the pdf link above and take a read of the first blog in the series.
This first blog focuses around the manufacture of cell and gene therapies with an interesting analogy to the automotive industry. It also looks at how 3P innovation can help with the manufacture of these life-changing ATMPs.
In early-stage pharmaceutical development, poor powder flow is rarely the root issue, it’s simply a symptom. The real challenge for formulation...
Pouches are widely used in medical device packaging to provide a sterile barrier when the device itself, or its primary container, cannot inherently...
Dose Delivery Uniformity (DDU) is one of the most persistent challenges in dry-powder inhaler development, and few have tackled it more directly...